Publication Name	World Journal of Stem Cells
Manuscript ID	57915
Country	South Korea

Received	2020-06-30 03:22
Peer-Review Started	2020-06-30 03:23
To Make the First Decision
Return for Revision	2020-10-21 20:23
Revised	2020-10-23 01:28
Second Decision	2020-11-11 09:38
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2020-11-12 16:59
Articles in Press	2020-11-12 16:59
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-12-24 08:42
Publish the Manuscript Online	2020-12-27 05:30

ISSN	1948-0210 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cell Biology
Manuscript Type	Review
Article Title	Prospects for the therapeutic development of umbilical cord blood-derived mesenchymal stem cells
Manuscript Source	Invited Manuscript
All Author List	Soyoun Um, Jueun Ha, Soo Jin Choi, Wonil Oh and Hye Jin Jin
Funding Agency and Grant Number
Corresponding Author	Hye Jin Jin, PhD, Director, Director, Senior Researcher, Biomedical Research Institute, MEDIPOST Co., Ltd., 21, Daewangpangyo-ro 644-gil, Bundang-gu, Seongnam 13494, South Korea. genny77@medi-post.co.kr
Key Words	Umbilical cord blood; Mesenchymal stem cell; Stem cell therapy; Immunomodulation; Regenerative medicine; Therapeutic cell manufacturing processing
Core Tip	Umbilical cord blood (UCB) is a primitive and rich source of mesenchymal stem cells (MSCs). UCB-derived MSCs have the potential of exerting profound immunomodulatory effects with the secretion of factors and cytokines. However, the safety and yield of UCB-derived MSCs are still a concern. Next-generation stem cell therapy is necessary, referring to the mass production of efficient stem cells based on the fundamental technology, to improve whole cell processing.
Publish Date	2020-12-27 05:30
Citation	Um S, Ha J, Choi SJ, Oh W, Jin HJ. Prospects for the therapeutic development of umbilical cord blood-derived mesenchymal stem cells. World J Stem Cells 2020; 12(12): 1511-1528
URL	https://www.wjgnet.com/1948-0210/full/v12/i12/1511.htm
DOI	https://dx.doi.org/10.4252/wjsc.v12.i12.1511

Full Article (PDF)	WJSC-12-1511.pdf
Full Article (Word)	WJSC-12-1511.docx
Manuscript File	57915_Auto_Edited.docx
Answering Reviewers	57915-Answering reviewers.pdf
Audio Core Tip	57915-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	57915-Conflict-of-interest statement.pdf
Copyright License Agreement	57915-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	57915-Language certificate.pdf
Peer-review Report	57915-Peer-review(s).pdf
Scientific Misconduct Check	57915-Bing-Ma YJ-1.jpg
Scientific Misconduct Check	57915-Bing-Liu M-2.PNG
Scientific Misconduct Check	57915-Scientific misconduct check.pdf
Scientific Editor Work List	57915-Scientific editor work list.pdf
CrossCheck Report	57915-CrossCheck report.pdf